Verastem ^{Priced, Nasdaq: VSTM}

Pre-clinical stage biotech developing stem cell therapies for metastatic cancers.

Industry: Health Care

First Day Return: +10.9%

VSTM

Pre-clinical stage biotech developing stem cell therapies for metastatic cancers.

IPO News for Verastem

Busy pricing period ahead after 7 companies set terms last week 01/30/12
Verastem prices upsized IPO at $10 midpoint 01/26/12
3 U.S. IPOs planned for the week of Jan 23 01/23/12

IPO Data
IPO Date	01/26/2012
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$55
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Cambridge, MA, United States
Founded	2010
Employees at IPO	18
Website www.verastem.com

IPO News for Verastem

Busy pricing period ahead after 7 companies set terms last week 01/30/12
Verastem prices upsized IPO at $10 midpoint 01/26/12
3 U.S. IPOs planned for the week of Jan 23 01/23/12

Verastem (VSTM) Performance